Insulet (NASDAQ:PODD) Price Target Raised to $388.00

Insulet (NASDAQ:PODD) had its target price hoisted by The Goldman Sachs Group from $375.00 to $388.00 in a report issued on Friday morning,MarketScreener reports. The Goldman Sachs Group currently has a buy rating on the medical instruments supplier’s stock.

Other equities research analysts also recently issued research reports about the company. Sanford C. Bernstein lifted their target price on Insulet from $400.00 to $410.00 in a research report on Friday. Piper Sandler increased their price target on shares of Insulet from $320.00 to $360.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Morgan Stanley restated an “overweight” rating on shares of Insulet in a report on Thursday, August 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Insulet in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus began coverage on shares of Insulet in a research report on Tuesday, October 21st. They issued a “buy” rating and a $370.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $371.38.

Insulet Stock Down 1.1%

Shares of NASDAQ:PODD opened at $319.82 on Friday. Insulet has a 52-week low of $230.05 and a 52-week high of $353.50. The stock has a market cap of $22.51 billion, a P/E ratio of 97.21, a PEG ratio of 2.64 and a beta of 1.39. The business has a fifty day moving average of $325.06 and a two-hundred day moving average of $310.30. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, topping the consensus estimate of $1.13 by $0.11. The business had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company’s quarterly revenue was up 29.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.08 EPS. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, research analysts expect that Insulet will post 3.92 earnings per share for the current year.

Insiders Place Their Bets

In other news, SVP Prem Singh sold 687 shares of the stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. This trade represents a 17.00% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.39% of the stock is owned by company insiders.

Hedge Funds Weigh In On Insulet

Several hedge funds have recently added to or reduced their stakes in the stock. True Wealth Design LLC boosted its holdings in shares of Insulet by 288.0% in the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 72 shares in the last quarter. Zions Bancorporation National Association UT acquired a new position in Insulet in the first quarter valued at $26,000. Larson Financial Group LLC boosted its stake in Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 81 shares in the last quarter. Golden State Wealth Management LLC grew its holdings in shares of Insulet by 202.9% during the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after purchasing an additional 69 shares during the last quarter. Finally, SouthState Corp increased its position in shares of Insulet by 253.3% during the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 76 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.